Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Expands Bladder Cancer Collaboration with Vancouver Prostate Centre

Premium

MDRNA said last week that it has extended and expanded its collaboration with the Vancouver Prostate Centre to discover and develop RNAi-based drugs for bladder cancer.

The company said it first began working with VPC in 2008 to investigate the use of its DiLA2 delivery platform and UsiRNA molecules in one of the center's bladder cancer models.

"In light of current results demonstrating efficient delivery and high potency for RNAi, the program will expand to evaluate UsiRNAs targeting other critical pathways in cancer, the impact on tumor biology, tumor growth, and survival rates," MDRNA said.

Earlier this year, MDRNA announced that it had added bladder cancer to its formal pipeline after its collaboration with VPC had yielded positive results in a rodent model of bladder cancer (see RNAi News, 8/6/2009).

MDRNA has said that it could file an investigational new drug application to begin human trials of the bladder cancer therapy next year.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.